Dongsung Kim

Dongsung Kim

Auto-generated profile, based on publicly available information

Dongsung Kim

Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
DKDongsung Kim
Dongsung Kim
LHLorenz Herdeis
Lorenz Herdeis
DRDorothea Rudolph
Dorothea Rudolph
YZYulei Zhao
Yulei Zhao
JBJark Böttcher
Jark Böttcher
PLPiro Lito
Piro Lito
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients1–7. Whether inactive-state selective inhibition can be used to therapeutically target non-G12C KRAS mutants remains under investigation. Here we report the discovery and characterization of a non-covalent inhibitor that binds preferentially and with high affinity to the inactive state of KRAS while sparing NRAS and HRAS. Although limited to only a few amino acids, the evolutionary divergence in the GTPase domain of RAS isoforms was sufficient to impart orthosteric and allosteric constraints for KRAS selectivity. The inhibitor blocked nucleotide exchange to prevent the activation of wild-type KRAS and a broad range of KRAS mutants, including G12A/C/D/F/V/S, G13C/D, V14I, L19F, Q22K, D33E, Q61H, K117N and A146V/T. Inhibition of downstream signalling and proliferation was restricted to cancer cells harbouring mutant KRAS, and drug treatment suppressed KRAS mutant tumour growth in mice, without having a detrimental effect on animal weight. Our study suggests that most KRAS oncoproteins cycle between an active state and an inactive state in cancer cells and are dependent on nucleotide exchange for activation. Pan-KRAS inhibitors, such as the one described here, have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.

18 August 2023 in Science
Verified
Journal Article
Closed access
CSChristopher J. Schulze
Christopher J. Schulze
KSKyle J. Seamon
Kyle J. Seamon
YZYulei Zhao
Yulei Zhao
YYYu C. Yang
Yu C. Yang
JCJim Cregg
Jim Cregg
PLPiro Lito
Piro Lito
The discovery of small-molecule inhibitors requires suitable binding pockets on protein surfaces. Proteins that lack this feature are considered undruggable and require innovative strategies for therapeutic targeting. KRAS is the most frequently activated oncogene in cancer, and the active state of mutant KRAS is such a recalcitrant target. We designed a natural product–inspired small molecule that remodels the surface of cyclophilin A (CYPA) to create a neomorphic interface with high affinity and selectivity for the active state of KRAS G12C (in which glycine-12 is mutated to cysteine). The resulting CYPA:drug:KRAS G12C tricomplex inactivated oncogenic signaling and led to tumor regressions in multiple human cancer models. This inhibitory strategy can be used to target additional KRAS mutants and other undruggable cancer drivers. Tricomplex inhibitors that selectively target active KRAS G12C or multiple RAS mutants are in clinical trials now (NCT05462717 and NCT05379985).

31 December 2006 in Ocean and Polar Research
Verified
Journal Article
Open access
JLJaehac Lee
Jaehac Lee
HCHyunwoo Choi
Hyunwoo Choi
JCJinho Chae
Jinho Chae
DKDongsung Kim
Dongsung Kim
SLSeungbaek Lee
Seungbaek Lee

12 November 2025 in Poultry Science
Verified
Journal Article
Open access
MWMichelle Wright
Michelle Wright
WCWonjun Choi
Wonjun Choi
ZDZhijie Deng
Zhijie Deng
DKDongsung Kim
Dongsung Kim
KLKichoon Lee
Kichoon Lee
Poultry, including birds such as chicken, duck, turkey, geese, and other game birds is the most widely consumed animal protein globally, with per capita poultry consumption steadily rising in the United States over the past several decades. To meet the demand for poultry, many avenues of improving poultry production have been explored including genetic modification solutions. While genetic modification in many poultry species has been well explored, gene editing in turkey has no research into its application. This study investigated the feasibility of using CRISPR/Cas9 mediated gene editing using adenoviral delivery in vitro, a method that has been proven successful for other species of poultry but never turkey. Three guide RNAs (gRNAs) were designed, targeting the leptin receptor (LEPR) gene matching the gene sequences of both chicken and turkey. Following the assessment of each gRNA's editing efficiency in turkey embryonic fibroblast (TEF) cells and commercially available chicken DF-1 cells via liposome-mediated transfection of the CRISPR vector, the most effective gRNA was chosen for recombinant adenovirus type 5 production. From there, both DF-1 and TEF cells were transduced using the adenovirus and the genome editing efficiency was assessed. The results show that turkey cells can be genetically modified in vitro with indel frequencies comparable to those observed in chicken cells, using both CRISPR plasmids and adenoviral vectors. These findings can lay the groundwork for future experiments and adaptation to in vivo modification of turkey in the future.

12 August 2026 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DKDasom Kim
Dasom Kim
JLJunhyung Isaac Lee
Junhyung Isaac Lee
DKDongsung Kim
Dongsung Kim